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A wealth of T- and B-cell abnormalities has been described in systemic lupus erythematosus (SLE). In general, T and B cells
manifest evidence of intense in vivo activation, yet perform poorly when tested for in vitro responsiveness to exogenous
antigen. The immune system behaves as if its commitment to self-responsiveness overrides the normal capacity to respond
to immunogenic challenges. Many irnmunoregulatory abnormalities have been characterized, but their relation to disease
remains controversial. Although a widely accepted unifying hypothesis for the vigorous autoantibody production and
associated immune deficiency of SLE is lacking, it seems certain that the profound abnormalities of T and B cells in SLE are
intertwined with the fundamental cause of this illness. J Invest Dermatol 100:69S–72S, 1993
There are probably more published studies of immune abnormalities
associated with systemic lupus erythematosus (SLE) than with any
other single illness. This is due to the striking array of autoantibodies
associated with this disorder, leading investigators to study SLE for
clues to fundamental principles of self-non-self discrimination. Whereas
there is as yet no single aberration that can be identified as the cause of
disease or autoantibody formation, many interesting findings have
emerged from which future insights will surely develop. The subject
has been reviewed extensively [1,2]. This manuscript will consider
themes that have evolved over many years of investigation and will
emphasize new findings.
THE GENERAL STATE OF THE IMMUNE SYSTEM IN SLE
Humoral Immunity Because SLE is characterized by vigorous formation
of antibody both to self and to certain random antigens, it is paradoxical
that antibody responses to deliberate immunization are not heightened,
and may indeed be impaired [3,4]. This is particularly true of patients
with active disease, but the immunosuppressive therapy often adminis-
tered to such individuals clouds this issue. It thus can not be the case that
the ‘‘thermostat’’ of the immune system is simply set higher in SLE.
Rather, there is a bias toward formation of autoantibodies and probably
autoreactive T cells (see below) against self components. Along with this
self-directed immune response comes suppression of responses to foreign
stimuli and an increased level of spontaneous polyclonal B-cell
activation.
Cellular Immunity Delayed hypersensitivity responses in vivo and
in vitro are generally impaired in SLE, even in patients not receiving
immunosuppression [5]. This may be partly due to lymphopenia
[6], but more specific regulatory abnormalities have also been
described [7].
LYMPHOCYTE ABERRATIONS IN SLE
There is controversy regarding which specific T-cell subsets are
diminished in SLE [8]. Despite reduced absolute numbers, those T cells
present in the circulation of patients with active SLE are in an activated
state, expressing HLA-DR and DP antigens [9,10] and secreting products
associated with activation [11]. When SLE T lymphocytes are isolated,
however, their in vitro response to mitogen stimulation is usually
deficient [12]. This defect is also seen in responsiveness to antigens [3,4],
and to allogeneic and autologous class II MHC molecules [13]. In part, it
reflects a reduced ability to generate interleukin 2 and perhaps other
T-cell-derived products [14]. Impaired T-cell function may be the result
of intrinsic T-cell defects, such as membrane signal transduction
anomalies [15–17]. Alternatively, T-cell dysfunction in SLE has been
attributed to anti-lymphocyte antibodies or, in somewhat circular
fashion, to the aberrant influence of other T lymphocytes [18,19]. There
is defective activation of SLE T lymphocytes through the CD2 pathway
[20], whereas activation via CD3 may be enhanced [21] or defective
[22]. It has been argued that reduced methylation of T-cell DNA may be
an underlying cause of the emergence of T-cell reactivity in SLE [23].
Among the more intriguing recent observations is the finding that SLE
patient blood contains increased numbers of T-cell receptor alpha-beta
positive T cells, which lack both CD4 and CD8 [24,25] (see below).
Interesting questions have been raised about the B cells in SLE and
their antibody products. The identification of a subset of B lymphocytes
(Bl cells, which express CD5 and generate mostly IgM, self-reactive
autoantibodies with little or no somatic mutation) has raised the question
of whether such cells might be important in disease [26,27]. In support of
this view, some IgM SLE autoantibodies have shown strong conservation
of germline V gene sequences [28]. More recent data indicate, however,
that SLE autoantibodies are the products of conventional (B2) B cells
[29,30]. Additionally, at least one IgG anti-DNA antibody has undergone
extensive somatic mutation [31], which implies a role for antigen in
driving the production of this autoantibody. Whether there is a bias
toward the use of certain V genes is so far unclear. B cells from SLE
patients are the source of heightened cytokine secretion, and may express
fundamental functional abnormalities [32,33]. Such appears to be the
case in the Ipr model of murine SLE, in which only SLE B cells can
produce autoantibodies in chimeras that possess B cells from both SLE
and non-SLE mice [34].
ROLE OF T AND B CELLS IN SLE PATHOGENESIS
The role of B cells in SLE is easy to define. They are the source of
autoantibodies, some of which are harmful, others of which may serve as
useful diagnostic markers. By contrast, it is astonishing that so little is
known of the contribution of T cells to the disease manifestations of SLE.
As antibody-mediated damage has been shown to account for only a few
0022-202X/93/$06.00 Copyright & 1993 by The Society for Investigative Dermatology, Inc.
69S
Departments of Medicine and Microbiology/Immunology, University of North
Carolina School of Medicine, Chapel Hill, North Carolina, U.S.A.
Reprint requests to: Dr. Philip L. Cohen, Departments of Medicine and
Microbiology/Immunology, University of North Carolina School of Medicine,
Chapel Hill, NC 27599-7280.
Abbreviations: MHC, major histocompatibility complex; SLE, systemic lupus
erythematosus
of the many manifestations of SLE, it seems reasonable to consider that
T-cell - mediated injury is responsible for at least some of the inflammatory
findings in SLE. Partly because of logistic considerations, there is only
scattered evidence to support this view. T lymphocytes, both CD4 and
CD8, are found in the cutaneous lesions of SLE [35]. Whether they
directly mediate injury, provide help to other cells, or are simply
bystanders is uncertain and difficult to know.
SLE autoantibodies can be present in impressive concentrations.
Because they are mainly of the IgGl subclass and directed at protein
antigens [36], it is likely that T lymphocytes are essential in providing
help to autoantibody-producing B cells.
Delayed hypersensitivity to nuclear antigens in SLE has been reported
occasionally[5]; the demonstration of SLE T-cell recognition of autoanti-
gen in patients with high levels of the appropriate serum autoantibody
has been elusive. Even in SLE animal models, autoantigen-reactive T cells
have been difficult to demonstrate and footpad immunization with
autoantigen has been necessary [37].
It is possible that the failure to see SLE-related T-cell recognition
of autoantigen reflects the inadequacy of assays (for myasthenia
gravis, for example, enumeration of IFN-gamma secreting T cells is
reported to be a more sensitive measure of reactivity to the nicotinic
acetylcholine receptor [38]), or is simply due to the inherent limitations
in sampling the peripheral blood, instead of the lesions or central
lymphoid organs where antigen-reactive T cells might be more likely
to reside.
Regardless of the nature of the antigen recognized by SLE T
lymphocytes, persuasive evidence argues for their participation in
autoantibody formation. In vitro, SLE T cells are necessary for the
continued production in vitro of autoantibodies [39]; a CD8 þ cell may
be crucial in this regard [40]. The interaction of T cells and B cells may be
restricted by class II major histocompatibility molecules [41]. Some of the
most provocative new data concern the possibility that a minor
population of T cells expressing the ab form of the T-cell receptor yet
lacking both the CD4 and CD8 determinants may be responsible for
providing help for pathogenic SLE autoantibodies [24,25].
Although the weight of evidence favors T-cell participation in SLE
autoantibody production, it is possible that autoantigen-specific B cells,
surrounded as they are by an ample source of antigen, can produce
autoantibodies with only a minimum of T-cell help. The polymeric nature
of DNA may also be relevant, as T-independent antigens generally are
macromolecules that display repetitive determinants. In animal models, it
has been shown that the continued production in vitro of the SLE-specific
anti-Sm response is dependent only on nonspecific T-cell products, such
as IL-2 [42].
The lack of readily demonstrable autoantigen-specific T cells in SLE
may also imply that T-cell help takes a different form in the chronic
production of autoantibodies. Perhaps antigen-specific T cells are needed
early in the course of autoantibody responses. Once initiated, such
antibody production may proceed with T-cell help of a nonspecific
nature, mediated either through accessory molecule interactions such as
CD5-CD72 or ICAM-LFA1, or by the local secretion of cytokines. Several
laboratories have observed heightened spontaneous production of B-cell-
activating factors in patients with active disease. Of interest in this regard
are recent reports of enhanced IL-6 production in SLE [43,44].
Additionally, it is possible that SLE B cells engaged in antibody
production are less discriminating or more sensitive in their requirements
for T cells or T-cell factors [45,46].
The chronic graft-versus-host model of SLE may be instructive in light
of the above. Here, autoantibodies typical of SLE are produced as a result
of the recognition of class II MHC products by grafted T cells [47].
Although this abnormal form of T-B collaboration may not occur in
spontaneous SLE, the model does demonstrate that autoreactive B cells
are readily stimulated in normal individuals by direct contact with T cells
reactive with MHC molecules.
DOES ANTIGEN PROVOKE AUTOANTIBODY
PRODUCTION IN SLE?
For responses to exogenous antigenic stimulation, it is tautologic that
antibodies arise in response to immunization with antigen. In systemic
autoimmunity, other mechanisms are possible, such as spontaneous
B-cell activation, cross-reactivity with environmental antigens, or idiotypic
stimulation. In SLE, much recent evidence favors the immunogenicity of
self antigens. The frequent occurrence of antibodies to multiple
determinants of complex antigens such as Sm in the serum of patients
is hard to explain by mechanisms other than antigenic stimulation.
Further analysis of specific epitopes recognized by such autoantibodies
has revealed even more complexity, reinforcing the notion of an antigen-
driven response. The presence of somatic mutations in autoantibodies
also favors an antigen-driven mechanism (see above), and animal
experiments indicate that nuclear antigens can initiate and perpetuate
an autoantibody response both in vivo and in vitro.
SOME IMMUNOLOGICALLY BASED THEORIES OF
SLE PATHOGENESIS
The SLE literature is fraught with attempts to explain all or most of the
immune abnormalities of this disease by a single lesion. Although such
approaches are inevitably oversimplified, important testable hypotheses
may arise. Some recent themes in conceptualizing SLE pathogenesis are
presented below.
Loss of Suppressor Cells Of the many theories of SLE pathogenesis, few
have held so much appeal as the notion that the disease is a result of the
loss of suppressor T lymphocytes. The consequences of this event, which
might be mediated by anti-lymphocyte antibodies, should be a global
loss of immunoregulation that could lead to unbridled autoantibody
production. Strong early support for this notion came from animal models
of SLE, although this could not be sustained in light of numerous
contradictory reports and in the face of a better understanding of the
immune system. Nevertheless, many reports of suppressor-cell dysfunc-
tion in human SLE appeared in the late 1970s to the mid 1980s, and the
concept of suppressor-cell dysfunction was repeated in many general and
specialty textbooks.
The waning of support for the suppressor-cell dysfunction theory of
SLE accelerated with the realization among most immunologists that
suppressor T cells themselves were nearly impossible to clone and
expressed a non-existent or at least elusive gene product (I-J). Their
surface receptors proved impossible to isolate and had binding
characteristics unlike those of the newly discovered T-cell receptor.
Clinical immunologists concerned with SLE thus found themselves
abandoned by most basic immunologists, many of whom now openly
doubted the reality of suppressor cells [48].
Excessive Polyclonal B-Cell Activation Excessive polyclonal B-cell
activation provides another attractive framework from which to view
the many abnormalities of SLE [49]. There is undoubtedly a component
of nonspecific B-cell activation in SLE, as demonstrated by generalized
increases in immunoglobulins and circulating activated B cells [50,51].
Yet this view fails to account for the disproportionate increase in
autoantibodies, which are increased thousands of times over levels found
in normals, in contrast to the severalfold increase in antibody to
trinitrophenol or to viral antigens [52]. Further, recent evidence that SLE-
specific autoantibodies are the products of B cells that have undergone
selection argues strongly against polyclonal activation as the sole cause
of autoantibody production in SLE. It may well be, however, that
polyclonal B cell activation is an important indication of an underlying
state of increased B-cell susceptibility to antigenic stimulation, which in
turn predisposes to the development of autoimmunity.
Inappropriate T-Cell Help A potentially instructive model of SLE
autoantibody formation is that of chronic graft-versus-host disease.
Infusion of T lymphocytes reactive against class II MHC molecules
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provokes the production of an array of SLE-related autoantibodies and the
development of glomerulonephritis [47]. The T-cell-B-cell interactions
require direct cell-cell contact [53]. We have argued that aberrant
recognition of self-class IIMHC antigens could explain many of the
abnormalities of human SLE [54].
Disordered Autoantigen Processing Exogenous antigens are ingested by
antigen-presenting cells, primarily B cells, and are broken down into
peptides by lysosomal proteases. Specific chaperonins serve to transport
surface-bound class II MHC molecules into specialized lysosomal
compartments, where they encounter relevant peptides that displace
the invariant chain and bind in the antigen-binding groove [55].
These relatively recent advances in the understanding of antigen
processing suggest interesting potential mechanisms for the genesis of
serologic autoreactivity to self-protein antigens. As indicated above, SLE
autoantibody responses are probably autoantigen-driven. What is the
source of the protein autoantigens? Without a firm experimental basis, it
is generally believed that self-protein antigens, particularly those arising
from nuclei, become available in immunogenic form as a consequence
of cell death and liberation of nuclear contents. Whereas this
phenomenon is easy to detect in vitro, its in vivo significance is
unknown. Such cell-derived nuclear antigens might be associated with
the nuclear matrix, or might exist free in the extra-cellular fluid.
Phagocytosis and antigen presentation would need to occur in order
for immunogenic peptides to be recognized by T lymphocytes. If this
phenomenon were occurring to any significant degree in SLE patients
with ongoing responses against nuclear antigens, one would expect the
expansion of clones of autoantigen-reactive T lymphocytes. The paucity
of evidence for such cells has been discussed above. Nevertheless, it is
possible that an aberration anywhere in the complex pathway of antigen
presentation could lead to the formation of immunogenic fragments of
self antigens in vivo in SLE patients; such anomalous processing might
not be readily detectable using conventional cell culture systems, which
rely on the antigen-processing capabilities of peripheral blood mono-
cytes, a population that has arisen freshly from the bone marrow and
might not express an acquired defect in processing.
It is also possible that self antigens in SLE are processed from within
antigen-processing cells. Although class I MHC antigens have been
identified as restriction elements for most intracellular antigens recog-
nized by T cells, the use of class II MHC molecules has been recently
demonstrated for several antigens derived from within cells [56]. The
processing of self proteins, such as nuclear antigens, may reflect a
fundamental pathogenic mechanism in autoimmune diseases. Perhaps at
the clonal level, antigen-presenting cells may acquire the ability to
present self proteins that normally are kept out of the antigen-presenting
compartments. One can visualize that a lesion in transport proteins, or in
intracellular sorting, might be responsible for the inappropriate presenta-
tion of self antigens to T cells. Such a phenomenon would explain the
failure to observe anamnestic responses in vitro to self proteins presented
from the ‘‘outside in,’’ as these may be processed in a completely
different manner. A lesion in antigen processing might even be linked to
alleles at the major histocompatibility complex, as transport proteins
have been observed to be encoded near this locus. Furthermore, dynamic
changes in the populations of cells presenting or not presenting self
antigens might account for the temporal and anatomical variation of
disease activity in SLE. Mononuclear phagocyte abnormalities have been
reported in SLE, and may vary with disease activity [57].
The observation that autoantibody production can be provoked by
repeated immunization in no way speaks against this proposed
mechanism, as processing from the outside in of nuclear antigens
might provide an alternative and artifactual way of inducing autoanti-
bodies. A disorder of antigen presentation could explain the hyporespon-
siveness of SLE patients to exogenous antigens, as the antigen-processing
machinery might be diverted away from normal responses to exogenous
antigens.
PERSPECTIVES FOR THE FUTURE
Recent conceptual and technological advances allow the cautious hope
that new immunologic insights in SLE pathogenesis are forthcoming. An
increased understanding of the basic mechanisms of T-and B-cell tolerance
from new animal models, such as transgenic animals, promises to cast light
on self-nonself recognition in pathologic states such as SLE. The disease-
related implications of a new understanding of the nature of the T-cell
receptor-antigen/MHC interaction are not yet clear, but seem substantial.
Intense interest in the cell biology of antigen presentation may lead to a
new understanding of the immunogenicity of nuclear antigens.
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